Physician profile
John Morello
NPI 1720272644
$10,275.61
in general payments reported to CMS, 2019-2025
27 companies · $1,434 in 2025
The $1,434 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,616 · 2020: $350 · 2021: $1,139 · 2022: $1,563 · 2023: $1,902 · 2024: $1,272 · 2025: $1,434.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,591 · Education: $17.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,590.64 |
| Education | $17.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,114.80 | 2019-2025 | |
| Incyte Corporation | $1,105.49 | 2021-2025 | Opzelura, Opzelura |
| Journey Medical Corporation | $988.90 | 2019-2025 | |
| Genzyme Corporation | $663.07 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $655.80 | 2019-2025 | Dupixent, Libtayo |
| Ucb, INC. | $512.76 | 2019-2025 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $460.83 | 2021-2025 | Winlevi, Absorica Ld |
| Almirall LLC | $459.88 | 2019-2025 | Klisyri |
| Galderma Laboratories, L.P. | $450.05 | 2019-2025 | Nemluvio, Epsolay |
| Novartis Pharmaceuticals Corporation | $388.30 | 2019-2025 | |
| Pfizer INC. | $377.91 | 2019-2024 | |
| Janssen Scientific Affairs, LLC | $351.91 | 2019-2022 | |
| Vyne Pharmaceuticals INC. | $341.59 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $338.22 | 2019-2025 | Cabtreo |
| Arcutis Biotherapeutics, INC. | $331.78 | 2023-2025 | Zoryve |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $312.24 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $245.95 | 2022-2025 | Sotyktu |
| Janssen Biotech, INC. | $242.48 | 2024-2025 | Tremfya |
| Lilly USA, LLC | $227.81 | 2019-2023 | Olumiant |
| Verrica Pharmaceuticals INC. | $167.41 | 2023-2024 | Ycanth |
| Boehringer Ingelheim Pharmaceuticals, INC. | $135.06 | 2023 | Spevigo |
| Encore Dermatology INC. | $95.59 | 2019 | |
| Organon LLC | $92.78 | 2025 | Vtama |
| Celgene Corporation | $81.06 | 2019 | |
| Amgen INC. | $60.08 | 2023 | Otezla |
| Sandoz INC. | $53.05 | 2022-2024 | Hyrimoz |
| Promius Pharma LLC | $20.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Morello listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.